Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating AsiDNA in combination with Olaparib in participants with recurrent solid tumors has completed; the stu…
-
CLINICAL_TRIALS withdrawal · 2024-09-19Clinical Trial Update: 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 trial evaluating 177Lu-PSMA-617 with Niraparib and abiraterone acetate plus prednisone for metastatic prostate cancer and castra…
-
CLINICAL_TRIALS research · 2024-09-05Clinical Trial Update: Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)
This entry notes a recruiting clinical trial evaluating circulating tumor DNA as a biomarker to assess and predict the efficacy of PARP inhi…
-
CLINICAL_TRIALS research · 2024-09-05Clinical Trial Update: Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer [Phase 3]
A Phase 3 trial evaluating metastasis-directed therapy for oligoprogressive disease in men with castration-resistant prostate cancer is curr…
-
CLINICAL_TRIALS trial_result · 2024-09-03Clinical Trial Update: Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer [Phase 1]
This update reports the completion of a Phase 1 study of TAS3681 in metastatic castration-resistant prostate cancer.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-08-29Clinical Trial Update: Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC) [Phase 2]
Phase 2 study of ODX (Osteodex) in metastatic castration-resistant prostate cancer has completed.
-
CLINICAL_TRIALS research · 2024-08-20Clinical Trial Update: ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors [Phase 2]
Phase 2 study ARTEMIS-003 evaluating HS-20093 in metastatic castration-resistant prostate cancer and advanced solid tumors is currently recr…
-
CLINICAL_TRIALS withdrawal · 2024-08-19Clinical Trial Update: HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 3]
Phase 3 trial HC-1119 versus enzalutamide for metastatic castration-resistant prostate cancer has been terminated; no results are provided i…
-
CLINICAL_TRIALS research · 2024-08-14Clinical Trial Update: Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study [Phase 1]
A Phase 1 dose-escalation study evaluating 161Tb-SibuDAB, a new PSMA-targeted radioligand therapy, in metastatic castration-resistant prosta…
-
CLINICAL_TRIALS trial_result · 2024-08-09Clinical Trial Update: A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors [Phase 1]
Phase 1 study evaluating the safety, pharmacokinetics, and preliminary efficacy of the oral SM08502 with hormonal therapy or chemotherapy in…
-
CLINICAL_TRIALS research · 2024-08-09Clinical Trial Update: Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC） [EARLY_Phase 1]
An early Phase 1 trial evaluating [177Lu]Lu-PSMA-137 for metastatic castration-resistant prostate cancer, with not-yet-recruiting status and…
-
CLINICAL_TRIALS trial_result · 2024-08-01Clinical Trial Update: Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC [Phase 1]
An open-label Phase 1b dose-escalation trial of a micellar docetaxel formulation in metastatic castration-resistant prostate cancer has been…
-
CLINICAL_TRIALS trial_result · 2024-07-31Clinical Trial Update: Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib [Phase 2]
Phase 2 clinical trial update assessing bone response in metastatic castration-resistant prostate cancer patients treated with cabozantinib.
-
CLINICAL_TRIALS research · 2024-07-31Clinical Trial Update: Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment
A clinical trial evaluating organoid-based drug sensitivity screening to guide treatment for metastatic castration-resistant prostate cancer…
-
CLINICAL_TRIALS trial_result · 2024-07-24Clinical Trial Update: The Safety and Dosimetry Study of 177Lu-LNC1003 Injection [Phase 1]
Phase 1 safety and dosimetry study of the radiopharmaceutical 177Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer…
-
CLINICAL_TRIALS trial_result · 2024-07-18Clinical Trial Update: A COMbined progRamme of Exercise and Dietary ADvice in mEn With Castrate Resistant Prostate Cancer [NA]
This clinical trial update reports the completion of a study examining a combined exercise and dietary advice program for men with castratio…
-
CLINICAL_TRIALS trial_result · 2024-07-17Clinical Trial Update: Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone
A completed real-world study in Taiwan assessing the safety profile and how Radium-223 dichloride behaves in routine clinical practice for c…
-
CLINICAL_TRIALS trial_result · 2024-07-16Clinical Trial Update: ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer [Phase 2]
Phase 2 trial evaluating ESK981 in combination with Nivolumab for metastatic castration-resistant prostate cancer was terminated; results we…
-
CLINICAL_TRIALS research · 2024-07-15Clinical Trial Update: Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer. [Phase 2]
Phase 2 clinical trial update evaluating Abiraterone Acetate in combination with Darxicilib or Dalpicilib for metastatic castration-resistan…
-
CLINICAL_TRIALS research · 2024-07-10Clinical Trial Update: 177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer [NA]
Update on a clinical trial evaluating 177Lu-PSMA-EB-01 in patients with metastatic castration-resistant prostate cancer; the study is curren…
-
FDA approval · 2024-07-09FDA Approved: ERLEADA — Supplemental Application (Janssen Products, LP)
FDA approved a supplemental application for ERLEADA (apalutamide) by Janssen Products, LP, prompting changes to the product labeling. The ac…
-
CLINICAL_TRIALS research · 2024-06-27Clinical Trial Update: Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC [Phase 2]
Phase 2 clinical trial evaluating docetaxel or cabazitaxel with or without darolutamide in metastatic castration-resistant prostate cancer; …
-
CLINICAL_TRIALS trial_result · 2024-06-21Clinical Trial Update: An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer [Phase 2]
Open-label Phase 2 study of tomivosertib (eFT508) in advanced castration-resistant prostate cancer has been terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2024-06-18Clinical Trial Update: A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors [Phase 1, Phase 2]
Clinical trial of NOX66 with external beam radiotherapy in metastatic castration-resistant prostate cancer and other solid tumors was termin…
-
CLINICAL_TRIALS trial_result · 2024-06-12Clinical Trial Update: Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects [Phase 4]
Phase 4 trial evaluating whether a reduced dose of enzalutamide reduces cognitive side effects in frail men with castration-resistant prosta…